Related coverage linked through entity extraction aliases.
Aug 03, 2026
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
Aug 09, 2026
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
Mar 25, 2026
New research challenges the theory that ketamine's psychedelic effects drive its therapeutic benefits for alcohol use disorder. A study of 96 participants found no link between ketamine's psychoactive experiences and improved abstinence rates. The findings suggest other mechanisms, such as brain network alterations, may explain ketamine's effectiveness in treating addiction.
Feb 22, 2026
The Pathways clinical trial into puberty blockers has been paused after the MHRA raised concerns about minimum age limits and unquantified long-term biological risks, with recruitment now suspended pending resolution.
Feb 21, 2026
The MHRA has raised new safety concerns about the PATHWAYS clinical trial investigating puberty blockers in young people with gender incongruence, pausing preliminary work until issues are resolved with sponsor King's College London.
